Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

In silico analysis of RET variants in medullary thyroid cancer: from the computer to the bedside.

Heineman TE, Joshi R, Cohen MA, Kuhel WI, Kutler DI.

Otolaryngol Head Neck Surg. 2015 Apr;152(4):650-4. doi: 10.1177/0194599815569709. Epub 2015 Mar 2.

PMID:
25733075
2.

Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2.

Moore SW, Appfelstaedt J, Zaahl MG.

J Pediatr Surg. 2007 Feb;42(2):326-32.

PMID:
17270543
3.

RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.

Krampitz GW, Norton JA.

Cancer. 2014 Jul 1;120(13):1920-31. doi: 10.1002/cncr.28661. Epub 2014 Apr 3. Review.

4.
5.

Impact of RET proto-oncogene analysis on the clinical management of multiple endocrine neoplasia type 2.

Toledo SP, dos Santos MA, Toledo Rde A, Lourenço DM Jr.

Clinics (Sao Paulo). 2006 Feb;61(1):59-70. Epub 2006 Mar 10. Review.

6.

Medullary thyroid carcinoma (MTC) and RET proto-oncogene: mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form.

Figlioli G, Landi S, Romei C, Elisei R, Gemignani F.

Mutat Res. 2013 Jan-Mar;752(1):36-44. doi: 10.1016/j.mrrev.2012.09.002. Epub 2012 Oct 8. Review.

PMID:
23059849
7.

M918V RET mutation causes familial medullary thyroid carcinoma: study of 8 affected kindreds.

Martins-Costa MC, Cunha LL, Lindsey SC, Camacho CP, Dotto RP, Furuzawa GK, Sousa MS, Kasamatsu TS, Kunii IS, Martins MM, Machado AL, Martins JR, Dias-da-Silva MR, Maciel RM.

Endocr Relat Cancer. 2016 Dec;23(12):909-920.

PMID:
27807060
8.

[Genotype-phenotype correlations in multiple endocrine neoplasia type 2].

Zhang XW, Wang JY, Zhang YB, Wan HF, Zhang B, Yan DG, Liu WS, Xu ZG, Tang PZ.

Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2016 Jul 7;51(7):538-41. doi: 10.3760/cma.j.issn.1673-0860.2016.07.011. Chinese.

PMID:
27480304
9.

Nationwide French Study of RET Variants Detected from 2003 to 2013 Suggests a Possible Influence of Polymorphisms as Modifiers.

Lebeault M, Pinson S, Guillaud-Bataille M, Gimenez-Roqueplo AP, Carrie A, Barbu V, Pigny P, Bezieau S, Rey JM, Delvincourt C, Giraud S, Veyrat-Durebex C, Saulnier P, Bouzamondo N, Chabbert M, Blin J, Mohamed A, Romanet P, Borson-Chazot F, Rohmer V, Barlier A, Mirebeau-Prunier D.

Thyroid. 2017 Dec;27(12):1511-1522. doi: 10.1089/thy.2016.0399. Epub 2017 Nov 3.

PMID:
28946813
10.

RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.

Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E, Sculli M, Miccoli P, Basolo F, Grasso L, Pacini F, Pinchera A.

J Clin Endocrinol Metab. 2007 Dec;92(12):4725-9. Epub 2007 Sep 25.

PMID:
17895320
11.

RET mutation p.S891A in a Chinese family with familial medullary thyroid carcinoma and associated cutaneous amyloidosis binding OSMR variant p.G513D.

Qi XP, Zhao JQ, Chen ZG, Cao JL, Du J, Liu NF, Li F, Sheng M, Fu E, Guo J, Jia H, Zhang YM, Ma JM.

Oncotarget. 2015 Oct 20;6(32):33993-4003. doi: 10.18632/oncotarget.4992.

12.

Molecular epidemiology of multiple endocrine neoplasia 2: implications for RET screening in the new millenium.

Machens A, Lorenz K, Sekulla C, Höppner W, Frank-Raue K, Raue F, Dralle H.

Eur J Endocrinol. 2013 Feb 15;168(3):307-14. doi: 10.1530/EJE-12-0919. Print 2013 Mar.

PMID:
23211574
13.

Molecular genetics and phenomics of RET mutations: Impact on prognosis of MTC.

Frank-Raue K, Rondot S, Raue F.

Mol Cell Endocrinol. 2010 Jun 30;322(1-2):2-7. doi: 10.1016/j.mce.2010.01.012. Epub 2010 Jan 18. Review.

PMID:
20083156
14.

RET codon 609 mutations: a contribution for better clinical managing.

Mian C, Sartorato P, Barollo S, Zane M, Opocher G.

Clinics (Sao Paulo). 2012;67 Suppl 1:33-6. Review.

15.

Modifying impact of RET gene haplotypes on medullary thyroid carcinoma clinical course.

Kaczmarek-Ryś M, Ziemnicka K, Pławski A, Budny B, Michalak M, Hryhorowicz S, Hoppe-Gołębiewska J, Boruń P, Gołąb M, Czetwertyńska M, Sromek M, Szalata M, Ruchała M, Słomski R.

Endocr Relat Cancer. 2018 Apr;25(4):421-436. doi: 10.1530/ERC-17-0452. Epub 2018 Jan 31.

PMID:
29386230
16.

Rare RET Variant p.D707E in a Chinese Pedigree with Hereditary Medullary Thyroid Carcinoma.

Zhang L, Li X, Li Q, Ge S, Chen M, Huang S, Chen B, Li P, Teng B, Xu J, Zhao S, Qi F, Zhang Y.

Pathobiology. 2017;84(3):152-160. doi: 10.1159/000448845. Epub 2016 Nov 1.

17.

Mutational analysis of the RET proto-oncogene in 71 Japanese patients with medullary thyroid carcinoma.

Shirahama S, Ogura K, Takami H, Ito K, Tohsen T, Miyauchi A, Nakamura Y.

J Hum Genet. 1998;43(2):101-6.

PMID:
9621513
18.
19.

Multiple endocrine neoplasia type 2.

Lodish M.

Front Horm Res. 2013;41:16-29. doi: 10.1159/000345667. Epub 2013 Mar 19.

PMID:
23652668
20.

A newly identified missense mutation in RET codon 666 is associated with the development of medullary thyroid carcinoma.

Yamazaki M, Hanamura T, Ito K, Uchino S, Sakurai A, Komatsu M.

Endocr J. 2014;61(11):1141-4. Epub 2014 Oct 15.

Supplemental Content

Support Center